Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23)

Beckman Coulter

Status: Completed

Conditions: HAV

Treatments: Diagnostic Test: Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays; Diagnostic Test: Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays

Study type: Observational

Funder types: Industry

Identifiers

NCT06289868

DC-TR23-0222

HAV-EU-11-23 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate the clinical performance supporting that intended purpose of the Access anti-HAV as an aid in the laboratory diagnosis of HAV infection and for detection of anti-HAV after vaccination and of the Access anti-HAV IgM assay as an aid in the laboratory diagnosis of acute or recent HAV infection, on the DxI 9000 Access Immunoassay Analyzer.

This study will be used to obtain CE mark for both Access anti-HAV and anti- HAV IgM assays.

Full description

The objective of this study is to determine the diagnostic accuracy of Access anti-HAV and Access anti-HAV IgM assays on the DxI 9000 Access Immunoassay Analyzer, measured as clinical sensitivity and specificity.

The testing will be performed using banked, de-identified, prospective and retrospective US leftover clinical samples, and fully-anonymized retrospective known anti-HAV IgM positive patient samples procured from sample vendors.

Enrollment: 1,409 patients

Sex: All

Ages: 2+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Subject inclusion criteria for the signs and symptoms (S/S), at risk (A/R), HAV test ordered, and Acute HAV Infection cohorts:

• Subjects ≥ 2 years of age

• Subject or legal guardian has signed the Informed Consent Form (ICF) (a minor may need to sign an Assent Form (AF) if required by IRB)

• Subjects who are willing to donate the required amount of blood

• Subjects qualified for one (1) or more of the following four (4) Cohorts:

  • Signs and symptoms (S/S);
  • At risk (A/R);
  • Presumed S/S or A/R (HAV test ordered) and
  • Acute HAV Infection (known anti-HAV IgM positive samples) - these samples are not subject to the individual informed consent and volume criteria.

Subject inclusion criteria for the vaccination cohort

• Subjects 2 years of age or older
• Subjects able to understand and willing to sign the ICF at both pre and post vaccination time points. Subject or legal guardian has signed the Informed Consent Form (a minor may need to sign an assent form if required by IRB)
• Subjects who are willing to donate the required amount of blood: 30 mL
• Subjects with no signs or symptoms of hepatitis as determined by a medical provider, no history of known exposure to HAV
• Subjects previously unvaccinated for HAV

Exclusion criteria

• Subjects who previously participated in the study
• Subjects who have received experimental or investigational drugs or treatments within four weeks of phlebotomy

Note for vaccination study: Subjects were screened for anti-HAV prior to vaccination, if positive they were excluded from the study.

Trial design

1,409 participants in 3 patient groups

At-risk and/or signs and symptoms patients of HAV infection and/or HAV test ordered patients

Description:

Frozen leftover serum samples from adult and pediatric patients: * From subjects exhibiting either jaundice or elevated total bilirubin or elevated serum ALT enzymes and one or more primary signs and symptoms of hepatitis infection, and/or * From subjects at-risk of HAV infection, and/or * From subjects for whom laboratory testing for hepatitis A was ordered by their healthcare providers.

Treatment:

Diagnostic Test: Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays

Known anti-HAV IgM positive patients

Description:

Frozen serum or EDTA retrospective known anti-HAV IgM positive leftover samples procured from sample vendors . These samples are known Positive for HAV IgM AND at least one of the following : * Positive HAV PCR result (within the last 28 days) OR * Jaundice (clinical assessment OR Total bilirubin result \>3.0 mg/dL) OR * Elevated ALT result (\> 200 IU/L)

Treatment:

Diagnostic Test: Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays

HAV Pre- and post-vaccinated patients

Description:

Frozen serum leftovers. A first sample was collected, and the US licensed and CE-marked vaccination series administered. A second sample was collected four (4) to ten (10) weeks after the complete vaccination series has been administered according to vaccine dosing instructions.

Treatment:

Diagnostic Test: Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays